7-azaindoline | 10592-27-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吲哚类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 7-azaindoline
• 英文别名: 2,3-dihydro-7-azaindole；2,3-Dihydro-1H-pyrrolo[2,3-b]pyridine
• CAS: 10592-27-5
• 化学式: C₇H₈N₂
• mdl: MFCD06659751
• 分子量: 120.154
• InChiKey: ZFFYPGZDXUPKNK-UHFFFAOYSA-N

物化性质

• 熔点：
  78-83 °C
• 沸点：
  114°C/10mmHg(lit.)
• 密度：
  1.23
• 溶解度：
  溶于甲醇
• 最大波长(λmax)：
  306nm(Cyclohexane)(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S36
• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2933990090
• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,3-Dihydro-1H-pyrrolo[2,3-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,3-Dihydro-1H-pyrrolo[2,3-b]pyridine
CAS number: 10592-27-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H8N2
Molecular weight: 120.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-azaindoline 在 氧气 、 sodium t-butanolate 作用下， 以 二甲基亚砜 为溶剂， 60.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 以63%的产率得到7-氮杂吲哚
  参考文献：
  名称：

  DMSO / t-BuONa / O2介导的饱和N-杂环的好氧脱氢。

  摘要：

  芳族N-杂环如喹啉，异喹啉和二氢吲哚是通过叔丁醇钠促进的DMSO溶液中饱和杂环的氧化脱氢而合成的。该反应在温和的反应条件下进行并且具有良好的官能团耐受性。机理研究表明，一种自由基途径涉及从底物的N–H键或α–C–H夺取二甲基自由基的氢以及随后氮或α-氨基烷基自由基的氧化。

  DOI：

  10.1021/acs.joc.9b03447
• 作为产物：
  描述：

  3-溴-2-氯吡啶 在 盐酸 、 platinum(IV) oxide 、 四(三苯基膦)钯 、 sodium azide 、 meso-tetraphenylporphyrin iron(III) chloride 、 氢气 、 锌 作用下， 以 四氢呋喃 、 乙醇 、 水 、 间二甲苯 、 苯 为溶剂， 反应 56.0h， 生成 7-azaindoline
  参考文献：
  名称：

  强脂肪族 C(sp3)-H 键的铁催化胺化

  摘要：

  发现了带有未活化的一级、二级和三级 CH 键的 1,2,3,4-四唑的分子内脱氮 C(sp3)-H 胺化的概念。这种催化胺化遵循前所未有的金属自由基活化机制。通过生物活性分子的短时间合成展示了所开发方法的实用性。此外，通过催化剂设计的对映选择性 C(sp3)-H 胺化已经开始了初步努力。总的来说，这项研究强调了 C(sp3)-H 键官能化化学的发展，它应该在药物发现和天然产物合成的背景下得到广泛应用。

  DOI：

  10.1021/jacs.0c07810
• 作为试剂：
  描述：

  4-甲基-1-戊烯 、 环戊酮 在 7-azaindoline 、 bis(1,5-cyclooctadiene)iridium(I) tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 、 N-叔丁基异丙醇胺 、 均三甲苯磺酸 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 neat (no solvent) 为溶剂， 反应 96.0h， 以25.926%的产率得到
  参考文献：
  名称：

  带有简单烯烃的环酮的支链选择性直接α-烷基化。

  摘要：

  在本文中，我们描述了以简单烯烃作为烷基化剂的环状酮的分子间直接支链选择性α-烷基化。通过烯胺-过渡金属的协同催化模式，α-烷基化反应可在原子经济和分步经济的方式下实现，并具有出色的支化选择性，可制备β-支化的酮。使用一对笨重的布朗斯台德酸和碱作为添加剂有助于提高效率。已获得有希望的对映选择性（74％  ee）。实验和计算机制研究表明，通过烯烃迁移插入Ir-C键然后CH-H还原消除的途径涉及高支化选择性。

  DOI：

  10.1002/anie.201900301

文献信息

• [EN] AZOLE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS D'AZOLE UTILISÉS EN TANT QU'INHIBITEURS DES PIM
  申请人：AMGEN INC

  公开号：WO2012129338A1

  公开（公告）日：2012-09-27

  The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及公式I和Ia的双环化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文所披露的化合物的药物组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症中的用途。
• Thrombin inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06610692B1

  公开（公告）日：2003-08-26

  Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein b is NY or O; c is CY2 or N; d is CY3 or N; e is CY4 or N; f is CY5 or N; g is CY6 or N; Y4, Y5, and Y6 are independently hydrogen, C1-4 alkyl, or halogen; Y1 and Y2 are independently hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, NH2, OH or C1-4 alkoxy, and Y3 is hydrogen, C1-4 alkyl, C3-7 cycloalkyl, halogen, —CN, NH2, OH or C1-4 alkoxy; A is and W, W1, R1, R3, R4, R5, X and Z are defined in the specification.

  发明的化合物在抑制凝血酶和相关血栓闭塞方面具有以下结构：或其药学上可接受的盐，其中b为NY或O；c为CY2或N；d为CY3或N；e为CY4或N；f为CY5或N；g为CY6或N；Y4、Y5和Y6独立地为氢、C1-4烷基或卤素；Y1和Y2独立地为氢、C1-4烷基、C3-7环烷基、卤素、NH2、OH或C1-4烷氧基，Y3为氢、C1-4烷基、C3-7环烷基、卤素、—CN、NH2、OH或C1-4烷氧基；A为，并且W、W1、R1、R3、R4、R5、X和Z在规范中有定义。
• [EN] N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS D'ACIDES AMINÉS N-ACYLE ET MÉTHODES D'UTILISATION
  申请人：PLIANT THERAPEUTICS INC

  公开号：WO2018049068A1

  公开（公告）日：2018-03-15

  The invention relates to compounds of formula (I), or a salt thereof wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ανβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.

  该发明涉及式(I)的化合物或其盐，其中R1、A、L、R2和n如本文所述。式(I)的化合物及其药物组成物是ανβ1整合素抑制剂，可用于治疗特定组织纤维化。
• Direct Catalytic Asymmetric Mannich-Type Reaction of α- and β-Fluorinated Amides
  作者：Lennart Brewitz、Fernando Arteaga Arteaga、Liang Yin、Kaliyamoorthy Alagiri、Naoya Kumagai、Masakatsu Shibasaki

  DOI：10.1021/jacs.5b11064

  日期：2015.12.23

  emergence of direct enolization protocols providing atom-economical and operationally simple methods to use enolates for stereoselective C-C bond-forming reactions, eliminating the inherent drawback of the preformation of enolates using stoichiometric amounts of reagents. In its infancy, direct enolization relied heavily on the intrinsic acidity of the latent enolates, and the reaction scope was limited

  过去二十年见证了直接烯醇化方案的出现，提供了原子经济且操作简单的方法来使用烯醇化物进行立体选择性 CC 键形成反应，消除了使用化学计量量的试剂预先形成烯醇化物的固有缺点。在其初期，直接烯醇化严重依赖潜在烯醇化物的固有酸性，反应范围仅限于易于烯醇化的酮和醛。该领域的最新进展使开发羧酸衍生物直接烯醇化成为可能，从而提供了合成通用手性构件的快速途径。尽管对富含对映体的含氟小分子的需求不断增长，由于竞争性和主导性的脱氟途径，α-和β-氟化羰基化合物在直接烯醇化化学中被忽略。在此，我们对 α- 和 β-氟官能化 7-氮杂吲哚啉酰胺的直接和高度立体选择性曼尼希型反应进行了全面研究，该反应依赖于软路易斯酸/硬布朗斯台德碱协同催化体系来保证有效的烯醇化，同时抑制不需要的脱氟。该协议有助于为药物化学提供一系列富含对映体的 β-氨基酸的氟化类似物。在此，我们对 α- 和 β-氟官能化 7-氮杂吲哚啉酰胺的直接
• [EN] MACROCYCLES AS PIM INHIBITORS<br/>[FR] MACROCYCLES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2014022752A1

  公开（公告）日：2014-02-06

  The invention relates to compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及式（1）的化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文所披露的化合物的药物组合物，以及它们在预防和治疗与Pim激酶相关的疾病和病症，尤其是癌症中的用途。